Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06756451RecruitingPhase 1
Experimental drug for relapsed or refractory AML
This trial tests an experimental drug (RJK-RT2831) for people with AML that has not responded to standard treatments. The drug targets two markers on leukemia cells (CD33 and CD123). The study is early-stage, aiming to find the right dose and check safety.
Hefei, AnhuiAges 18–74 - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06783790RecruitingPhase 2
Avapritinib combo for relapsed AML after transplant
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
TianjinAges 18 years+ - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT06793449RecruitingPhase 2
BCMA CAR-T vs. stem cell transplant for multiple myeloma
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
TianjinAges 18–70 - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06801002RecruitingPhase 1
Safety trial of JBZ-001 for advanced cancers
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
Columbus, OhioAges 18 years+ - NCT06809712RecruitingPhase 1
Stem cell transplant from a partially matched unrelated donor
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
HangzhouAges 18–60 - NCT06809699RecruitingPhase 1
Stem cell transplant using a partially matched family donor
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hangzhou, ChinaAges 18–60 - NCT06812507Recruiting
Umbilical cord blood transfer in very premature babies
This trial tests different ways of transferring blood from the umbilical cord to very premature babies (born at or before 32 weeks) to see if it can prevent complications of prematurity and improve their blood counts. It aims to find the best method for helping these vulnerable newborns.
AlexandriaAges 1 minute–2 minutes - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06821880Recruiting
Tracking infections and quality of life in blood cancer patients
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Innsbruck, TyroliaAges 18 years+ - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06829654Recruiting
Reimplanting frozen ovarian tissue in sarcoma and blood cancer survivors
This study looks at transplanting ovarian tissue that was frozen before cancer treatment to help restore fertility and hormone function in people who survived sarcomas or blood cancers. It aims to see if this procedure is safe and effective.
BolognaAges 18–38 - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06856226Recruiting
Drug metabolism study for stem cell transplant patients
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
Bethesda, MarylandAges 18–120 - NCT06857604Recruiting
Immune defects behind common blood diseases in young people
This study looks at how problems with the immune system might be linked to certain blood disorders in people under 25. The goal is to better understand what causes these conditions and find better ways to treat them.
Montreal, CanadaAges Up to 25 years - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06880393RecruitingPhase 2
BCMA CAR-T for high-risk multiple myeloma
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
TianjinAges 18–75 - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06886425Recruiting
Study of how azacytidine works in blood cancers
This study looks at how certain enzymes in your body affect the way a drug called azacytidine works against blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The goal is to better understand who might benefit most from this treatment.
MarseilleAges 18 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 601 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.